AU2012213576B2 - Bifidobacterium bifidum strains for application in gastrointestinal diseases - Google Patents

Bifidobacterium bifidum strains for application in gastrointestinal diseases Download PDF

Info

Publication number
AU2012213576B2
AU2012213576B2 AU2012213576A AU2012213576A AU2012213576B2 AU 2012213576 B2 AU2012213576 B2 AU 2012213576B2 AU 2012213576 A AU2012213576 A AU 2012213576A AU 2012213576 A AU2012213576 A AU 2012213576A AU 2012213576 B2 AU2012213576 B2 AU 2012213576B2
Authority
AU
Australia
Prior art keywords
strain
probiotic formulation
powder
probiotic
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012213576A
Other languages
English (en)
Other versions
AU2012213576A1 (en
Inventor
Simone GUGLIELMETTI
Diego Mora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synformulas GmbH
Original Assignee
Synformulas GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synformulas GmbH filed Critical Synformulas GmbH
Publication of AU2012213576A1 publication Critical patent/AU2012213576A1/en
Application granted granted Critical
Publication of AU2012213576B2 publication Critical patent/AU2012213576B2/en
Assigned to DR. FISCHER GESUNDHEITSPRODUKTE GMBH reassignment DR. FISCHER GESUNDHEITSPRODUKTE GMBH Request for Assignment Assignors: NATURWOHL PHARMA GMBH
Assigned to SYNFORMULAS GMBH reassignment SYNFORMULAS GMBH Request for Assignment Assignors: DR. FISCHER GESUNDHEITSPRODUKTE GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2012213576A 2011-01-31 2012-01-27 Bifidobacterium bifidum strains for application in gastrointestinal diseases Active AU2012213576B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11000744.0A EP2481299B1 (en) 2011-01-31 2011-01-31 Bifidobacterium bifidum strains for application in gastrointestinal diseases
EP11000744.0 2011-01-31
PCT/EP2012/051369 WO2012104226A1 (en) 2011-01-31 2012-01-27 Bifidobacterium bifidum strains for application in gastrointestinal diseases

Publications (2)

Publication Number Publication Date
AU2012213576A1 AU2012213576A1 (en) 2013-08-08
AU2012213576B2 true AU2012213576B2 (en) 2015-07-23

Family

ID=43901563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012213576A Active AU2012213576B2 (en) 2011-01-31 2012-01-27 Bifidobacterium bifidum strains for application in gastrointestinal diseases

Country Status (15)

Country Link
US (1) US9408879B2 (enExample)
EP (1) EP2481299B1 (enExample)
JP (1) JP5956467B2 (enExample)
CN (1) CN103476273A (enExample)
AU (1) AU2012213576B2 (enExample)
BR (1) BR112013019258B1 (enExample)
CA (1) CA2825980C (enExample)
DK (1) DK2481299T3 (enExample)
ES (1) ES2610908T3 (enExample)
HR (1) HRP20161792T1 (enExample)
HU (1) HUE033189T2 (enExample)
PL (1) PL2481299T3 (enExample)
PT (1) PT2481299T (enExample)
RU (1) RU2603285C2 (enExample)
WO (1) WO2012104226A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN103266076B (zh) * 2013-06-04 2014-10-29 神舟太空产品高科技成果推广中心集团有限公司 太空诱变高效两歧双歧杆菌、其应用及其胶囊制剂的制备方法
CN104546945A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 两歧双歧杆菌在治疗或预防类风湿性关节炎或其相关疾病中的用途
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
AR103260A1 (es) 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
KR20180030459A (ko) * 2015-03-09 2018-03-23 바이오이뮤나이저 에스에이지엘 항산화제와 비피도박테리아 및 프로바이오틱스로부터 분리된 세포벽이 조합된 조합물을 포함하는 항-노화 조성물
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
JP6637725B2 (ja) * 2015-10-28 2020-01-29 ビオフェルミン製薬株式会社 ウイルス感染症の予防及び／又は治療剤
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
ME03487B (me) 2016-03-04 2020-01-20 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
WO2017178315A1 (en) * 2016-04-14 2017-10-19 Dupont Nutrition Biosciences Aps Bifidobacteria for increasing lean body mass
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN106579414A (zh) * 2016-12-26 2017-04-26 北京康比特体育科技股份有限公司 一种缓解运动性腹泻的组合物
CN106834187B (zh) * 2017-03-06 2020-08-25 江南大学 一种两歧双歧杆菌及其用途
WO2018165563A1 (en) * 2017-03-09 2018-09-13 The Clorox Company Probiotic capsule and methods of preparing the same
JP2018177703A (ja) * 2017-04-14 2018-11-15 株式会社明治 Ｔｏｌｌ様受容体２活性化用組成物
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
CA3066189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
DK3745870T3 (da) * 2018-01-29 2023-02-20 Prec Group Limited Et kombinationsprodukt til profylakse og behandling af irritabel tarmsyndrom
KR102023700B1 (ko) * 2018-01-31 2019-09-20 주식회사 비피도 비피도박테리움을 함유한 류마티스관절염 개선용, 치료용 또는 예방용 조성물
WO2019243563A1 (en) 2018-06-22 2019-12-26 Synformulas Gmbh Non-viable bifidobacterium bifidum bacteria and uses thereof
CN112912088B (zh) * 2019-01-16 2024-12-24 N·V·努特里奇亚 用于轮状病毒引起的感染的具有非消化性寡糖的经发酵配方食品
IT201900011193A1 (it) * 2019-07-08 2021-01-08 Sofar Spa Ceppo di batteri Bifidobacterium bifidum, sue composizioni e relativi usi
EP4025299A4 (en) * 2019-09-05 2023-08-23 Superbrewed Food, Inc. MIXOTROPHIC PROBIOTIC COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF GAS
IT201900016811A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
CN118924795A (zh) * 2019-11-29 2024-11-12 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99提升肠道细菌感染抗性和肠道免疫力的应用
CN111110704B (zh) * 2020-02-14 2023-03-28 上海城建职业学院 一种益生菌菌剂、滴剂及其制备方法和应用
CN111743998A (zh) * 2020-06-04 2020-10-09 中通美雅生命健康(深圳)有限公司 用于辅助治疗肠炎组合物及其制备方法
RU2735717C1 (ru) * 2020-06-15 2020-11-06 Общество с ограниченной ответственностью "АВАН" Штамм Bifidobacterium bifidum, используемый в качестве пробиотика
CN116568314A (zh) * 2020-09-23 2023-08-08 Pbl生物实验室 新型乳酸菌及其用途
CN113943682B (zh) * 2020-11-12 2023-07-04 江南大学 缓解便秘的长双歧杆菌长亚种及其制备的发酵食品与益生菌制剂
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN112980734B (zh) * 2021-03-24 2022-07-22 江南大学 一株缓解便秘并调节肠道菌群紊乱的两歧双歧杆菌及其应用
CN113025526B (zh) * 2021-03-24 2022-09-27 江南大学 一株减少结肠病理损伤且具有缓解便秘作用的两歧双歧杆菌
CN113234619B (zh) * 2021-04-10 2022-07-05 江南大学 一株两歧双歧杆菌及其在缓解肠道损伤中的应用
CN116286439A (zh) * 2022-07-13 2023-06-23 四川大学 一株婴幼儿肠道来源的两歧双歧杆菌及应用
CN118291322A (zh) * 2022-07-13 2024-07-05 四川大学 一株婴幼儿肠道来源的两歧双歧杆菌
CN115838662A (zh) * 2022-11-02 2023-03-24 江南大学 一株具有缓解克罗恩病潜力的两歧双歧杆菌
JP2026505892A (ja) * 2023-03-21 2026-02-19 スーチュァン アナエロビック バイオテクノロジー カンパニー リミテッド プロバイオティクスおよびその使用
CN118044616A (zh) * 2023-09-05 2024-05-17 厦门大学 一种合生元及其用途
WO2025059424A1 (en) * 2023-09-15 2025-03-20 Biohm Health Inc. Pro-biotic compositions and methods for treatment of stress
CN118879582B (zh) * 2024-09-19 2025-03-25 微康益生菌(苏州)股份有限公司 一种细胞完整、分散均匀、稳定性强的后生元制备方法
CN121102165A (zh) * 2025-11-13 2025-12-12 厦门承葛生物科技有限公司 用于精准肠道菌群移植的肠道菌群胶囊及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
RU2152993C1 (ru) * 1999-11-30 2000-07-20 Государственный научный центр РФ Институт медико-биологических проблем Штамм bifidobacterium bifidum вкпм ас-1578, используемый для приготовления бактериальных препаратов и продуктов питания
RU2184146C1 (ru) * 2001-01-29 2002-06-27 Закрытое акционерное общество "Партнер" Штамм bifidobacterium bifidum 45 вкпм ас-1621, используемый для приготовления бактериальных препаратов и продуктов питания
KR100857500B1 (ko) * 2003-06-30 2008-09-08 클라사도 인크. 신규한 갈락토올리고사카라이드 조성물 및 그 제조방법
WO2006013588A1 (en) * 2004-08-05 2006-02-09 Anidral S.R.L. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
AU2006253007B2 (en) * 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
CN100490826C (zh) * 2005-07-05 2009-05-27 广州市微生物研究所 多联活性双歧杆菌产品的制备方法
WO2007010977A1 (ja) * 2005-07-21 2007-01-25 Kabushiki Kaisha Yakult Honsha 新規ビフィドバクテリウム属細菌及びその利用
US9084434B2 (en) * 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20080241226A1 (en) * 2007-03-27 2008-10-02 Abeln Susan L Methods and Kits For Administering Probiotics
EP2270133B1 (en) * 2008-04-22 2015-06-24 Corporación Alimentaria Peñasanta (Capsa) Method for obtaining a novel strain of bifidobacterium bifidum with activity against infection by helicobacter pylori
MX2010011995A (es) * 2008-05-01 2010-12-02 Procter & Gamble Metodos y estuches para el tratamiento de condiciones y trastornos inflamatorios del intestino.
SI2285387T1 (sl) * 2008-06-13 2016-02-29 N.V. Nutricia Prehrana za preprečevanje infekcij

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D1 : GUGLIELMETTI ET AL: "Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifdum to Caco-2 cells". Applied and Environmental Microbiology, 2008, vol. 74, no. 15, pages 4695-4702 *
D2 : GUGLIELMETTI ET AL: "Study of the adhesion of Bifidobacterium MIMBb75 to human intestinal cell lines". Current Microbiology, 2009, vol. 59, no. 2, pages 167-172 *

Also Published As

Publication number Publication date
EP2481299A1 (en) 2012-08-01
EP2481299B1 (en) 2016-12-07
PT2481299T (pt) 2017-03-08
JP2014505065A (ja) 2014-02-27
US9408879B2 (en) 2016-08-09
NZ613544A (en) 2014-10-31
RU2603285C2 (ru) 2016-11-27
BR112013019258B1 (pt) 2021-09-08
JP5956467B2 (ja) 2016-07-27
PL2481299T3 (pl) 2017-09-29
CA2825980A1 (en) 2012-08-09
DK2481299T3 (en) 2017-02-06
CN103476273A (zh) 2013-12-25
BR112013019258A2 (pt) 2016-10-11
ES2610908T3 (es) 2017-05-04
HUE033189T2 (en) 2017-11-28
HRP20161792T1 (hr) 2017-03-10
RU2013137404A (ru) 2015-03-10
BR112013019258A8 (pt) 2017-09-19
CA2825980C (en) 2017-10-24
US20140056852A1 (en) 2014-02-27
WO2012104226A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
AU2012213576B2 (en) Bifidobacterium bifidum strains for application in gastrointestinal diseases
AU2012213576A1 (en) Bifidobacterium bifidum strains for application in gastrointestinal diseases
Patel et al. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics
BRPI0616962A2 (pt) uso de lactobacillus para o tratamento de doenças autoimunes
JP2002534113A (ja) 炎症性疾患治療におけるビフィドバクテリウム（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ）
MX2013006460A (es) Bifidobacterium cect 7765 y su uso en la prevencion y/o tratamiento del sobrepeso, la obesidad y patologias asociadas.
CN101998834B (zh) 用于缓解胃肠道病症相关症状的益生菌
CN112218646A (zh) 一种组合物及其应用
Marx Immunoprotective effects of probiotics in the elderly
JP2008502606A (ja) 乳酸菌及び下痢の予防におけるそれらの使用
WO2019227414A1 (zh) 一种组合物及其应用
Arora et al. Therapeutic potential of probiotics: A ray of hope or nightmare?
JP7539163B2 (ja) ビフィドバクテリウム・ビフィダム非生菌及びその使用
US20220193155A1 (en) Microbial compositions and methods for greater tolerability and prolonged shelf life
CN118697770A (zh) 副干酪乳酪杆菌207-27在调节情绪方面的用途
CA3121419A1 (en) Phascolarctobacterium faecium for use in the prevention and treatment of obesity and its comorbidities
NZ613544B2 (en) Bifidobacterium bifidum strains for application in gastrointestinal diseases
RU2735717C1 (ru) Штамм Bifidobacterium bifidum, используемый в качестве пробиотика
Ringel What Are Probiotics and Do They Work in IBS?
Thayumanavan et al. Probiotics in gastroenterology
RU2724585C2 (ru) Пробиотическая композиция для восстановления микрофлоры кишечника и для профилактики синдрома избыточного бактериального роста и диарей и способ ее получения
Lee et al. Probiotics in health and disease
Renwick et al. Manipulating the gut microbiota
US20190091270A1 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
WO2025047884A1 (ja) 細菌、組成物及び組成物の製造方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DR. FISCHER GESUNDHEITSPRODUKTE GMBH

Free format text: FORMER APPLICANT(S): NATURWOHL PHARMA GMBH

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SYNFORMULAS GMBH

Free format text: FORMER OWNER(S): DR. FISCHER GESUNDHEITSPRODUKTE GMBH